Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Clinical evidence

LSD-assist

57 evidence topics · 4 sources

Objective
Location and study date
Study identifiers, dates, and status
Study design
Eligibility criteria
Inclusion criteria
CriterionQuoted registry text
Age“Age > 25 years.”
Anxiety diagnosis or severity“Meet DSM-IV criteria for anxiety disorder as indicated by the Structured Clinical Interview for the DSM (SCID)-IV or have a score of at least 40 on the state- or trait STAI scale at study inclusion.”
Proportion with life-threatening illness“40% or more of the participants should have a diagnosis of advanced-stage potentially fatal illness (autoimmune, neurological, or cancer without central nervous system (CNS) involvement).”
Life expectancy“Patients should be ambulatory and not terminal and likely to have a roughly estimated life expectancy of > twelve months.”
Participants without life-threatening illness“Patients without advanced-stage potentially fatal illness need to meet DSM-IV criteria for anxiety disorder (elevated STAI score not sufficient for inclusion)”
Psychiatric medication“Participants are willing to refrain from taking any psychiatric medications during the experimental session period.”
Washout of antidepressants and anxiolytics“If they are being treated with antidepressants or are taking anxiolytic medications on a fixed daily regimen such drugs must be discontinued long enough before the LSD/placebo treatment session to avoid the possibility of a drug-drug interaction (the interval will be at least 5 times the particular drug's half-life [typically 3-7 days]).”
Ongoing psychotherapy“If in ongoing psychotherapy, those recruited into the study may continue to see their outside therapist, provided they sign a release for the investigators to communicate directly with their therapist.”
Other psychoactive drugs“Participants must also refrain from the use of any psychoactive drugs, with the exception of the long term pain medication or caffeine or nicotine, within 24 hours of each LSD/placebo treatment session.”
Driving“Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after LSD/placebo administration.”
Treatment
Study outcomes
Rationale for using State-Trait anxiety inventory global score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Follow-up analysis set and statistical model
Results
Participant disposition
Baseline characteristics
Efficacy results
Follow-up at 12 months: remission and response
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary

NCT03153579 was an investigator-initiated phase 2 crossover trial at two centers in Switzerland (University Hospital Basel and a private practice in Solothurn), funded by University Hospital Basel and the Swiss Medical Society for Psycholytic Therapy. The registered summary planned 40 participants; 46 were enrolled, and 42 were included in the primary analysis. Because of carryover effects, the primary results are a between-subjects comparison of the first period, in which a STAI-G response (reduction of 30% or more) was reported for 13 of 20 participants (65%) receiving LSD and 2 of 22 (9%) receiving placebo. The response figures come from the May 2022 company announcement of an oral presentation; the primary publication reports the least-squares mean difference of -16.2 points (95% CI, -27.8 to -4.5) at 16 weeks.

The population combined participants with an anxiety disorder and participants with anxiety associated with a life-threatening illness, for whom a STAI score of 40 or more could substitute for a DSM-IV diagnosis; eligible diagnoses included generalized anxiety disorder, social phobia, and panic disorder, and the follow-up post hoc tests found no difference in STAI-G change between participants with and without a formal GAD diagnosis (P = 0.35 and P = 0.65). The primary endpoint was a self-reported questionnaire, and the follow-up authors state that no objective, interview-based data and no measure of expectancy were collected. The placebo-first group had higher symptom ratings at inclusion, a difference that remained throughout the trial.

Each participant received LSD 200 μg in two sessions of approximately 12 hours with one investigator or therapist, and study visits included talk therapy. The follow-up publication describes the study drug as LSD free base in an oral solution of 96% ethanol (100 μg per mL) with an ethanol-only placebo, while the registry describes placebo capsules containing mannitol. Most participants had received anxiolytics, antidepressants, or psychotherapy before entry, antidepressants were tapered only for the sessions, and the authors state that LSD served as an add-on treatment; the participants were described as having a long history of treatment attempts and failures, with anxiety diagnosed a mean of 10 years before inclusion.

The 12-month follow-up had no control group, since all participants had received LSD by then. Questionnaires were returned by mail by 35 participants, with 33 contributing STAI measures, and 6 participants continued psychedelic therapy in the Swiss limited-use programme with one to four additional LSD sessions. The authors state that it is largely unclear what therapy participants received between the end-of-study visit and follow-up. The primary publication reports transient, mild acute untoward effects in 8 participants (19%) and one treatment-related serious adverse event of acute transient anxiety (2%), which the company announcement describes as acute transient anxiety and delusions. The registry has no posted results.

Two authors are consultants for Mind Medicine, Inc., which licensed the knowhow and data owned by University Hospital Basel; the authors state that the company had no role in financing, planning, or conducting the follow-up study, and the company states that it has exclusive access and rights to the data.